ADMA Biologics Stock Financials

ADMA
 Stock
  

USD 3.24  0.12  3.57%   

ADMA Biologics Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 245.84 Million. The current year Average Equity is expected to grow to about 126.3 M, whereas Net Income Per Employee is forecasted to decline to (146.7 K).
  
With this module, you can analyze ADMA Biologics financials for your investing period. You should be able to track the changes in ADMA Biologics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

ADMA Biologics Most Recent Estimates

EPS Estimate Next Quarter
(0.07) 
Diluted Eps
(0.49) 
EPS Estimate Current Year
(0.33) 
EPS Estimate Next Year
(0.19) 
EPS Estimate Current Quarter
(0.08) 
Earnings Share
(0.49) 
Understanding current and past ADMA Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ADMA Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in ADMA Biologics' assets may result in an increase in income on the income statement.

Revenues

87.33 Million

The financial analysis of ADMA Biologics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for ADMA Biologics includes many different criteria found on its balance sheet. For example, investors should never minimize ADMA Biologics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor ADMA Biologics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in ADMA Biologics.

ADMA Biologics Cash

Chance Of Financial Distress
Less than 20
ADMA Biologics has less than 20 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for ADMA Biologics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in ADMA Biologics' official financial statements usually reflect ADMA Biologics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ADMA Biologics. For example, before you start analyzing numbers published by ADMA Biologics accountants, it's critical to develop an understanding of what ADMA Biologics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ADMA Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ADMA Biologics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ADMA Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ADMA Biologics. Please utilize our Beneish M Score to check the likelihood of ADMA Biologics' management to manipulate its earnings.

ADMA Biologics Company Summary

ADMA Biologics competes with Aurora Cannabis, Acer Therapeutics, and Agilent Technologies. ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Adma Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 527 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001368514
ISINUS0008991046
RegionNorth America
Business Address465 State Route
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.admabiologics.com
Phone201 478 5552
CurrencyUSD - US Dollar
You should never invest in ADMA Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of ADMA Biologics Stock, because this is throwing your money away. Analyzing the key information contained in ADMA Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

ADMA Biologics Key Financial Ratios

Generally speaking, ADMA Biologics' financial ratios allow both analysts and investors to convert raw data from ADMA Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of ADMA Biologics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that ADMA Biologics reports annually and quarterly.

ADMA Biologics Key Balance Sheet Accounts

201720182019202020212022 (projected)
Inventories12.63 M18.62 M53.06 M81.54 M124.72 M134.57 M
Receivables3.88 M1.39 M3.47 M13.24 M28.58 M30.83 M
Accounts Payable5.92 M5.9 M9.17 M11.07 M12.43 M13.41 M
Total Assets108.02 M88.88 M127.09 M207.67 M276.25 M298.06 M
Current Assets63.17 M44.53 M85.82 M153.74 M208.73 M225.21 M
Assets Non Current45.68 M44.35 M41.27 M53.93 M67.52 M72.85 M
Cash and Equivalents43.11 M22.75 M26.75 M55.92 M51.09 M55.12 M
Total Debt42.97 M44.1 M83.43 M93.33 M95.46 M102.99 M
Debt Non Current42.97 M44.08 M83.2 M92.97 M94.87 M102.36 M
Deferred Revenue2.69 M2.55 M2.4 M2.26 M2.12 M2.47 M
Shareholders Equity40.33 M19.77 M26.19 M88.25 M141.17 M152.32 M
Inventory12.63 M18.62 M53.06 M81.54 M124.72 M134.57 M
Total Liabilities67.69 M69.11 M100.9 M119.42 M135.08 M145.74 M
Current Liabilities9.44 M9.63 M14.03 M19.95 M30.38 M32.78 M

ADMA Biologics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what ADMA Biologics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Direct Expenses29.16 M42.19 M39.5 M61.29 M79.77 M86.07 M
Consolidated Income(43.76 M)(65.74 M)(48.28 M)(75.75 M)(71.65 M)(73.53 M)
Cost of Revenue29.16 M42.19 M39.5 M61.29 M79.77 M86.07 M
Gross Profit(6.4 M)(25.21 M)(10.16 M)(19.07 M)1.17 M1.27 M
Interest Expense3.29 M5.52 M8.99 M11.99 M13.06 M14.09 M
Net Income(43.76 M)(65.74 M)(48.28 M)(75.75 M)(71.65 M)(77.3 M)
Operating Expenses32.91 M35.08 M31.27 M45.84 M59.55 M64.25 M
Operating Income(39.31 M)(60.29 M)(41.42 M)(64.91 M)(58.37 M)(62.98 M)
Revenues22.76 M16.99 M29.35 M42.22 M80.94 M87.33 M

ADMA Biologics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of ADMA Biologics. It measures of how well ADMA Biologics is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money ADMA Biologics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money ADMA Biologics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what ADMA Biologics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(2.68 M)(2.1 M)(3.81 M)(12.72 M)(13.51 M)(13.87 M)
Depreciation Amortization and Accretion2.69 M3.45 M3.26 M3.94 M5.5 M5.93 M
Net Cash Flow or Change in Cash and Cash Equivalents38.69 M(21.85 M)(2.72 K)29.17 M(4.83 M)(4.96 M)
Issuance Purchase of Equity Shares39.21 M42.96 M48.47 M131.21 M121.14 M130.71 M
Issuance Repayment of Debt Securities21.54 M(36.28 K)38.03 M13.52 M(34.3 K)(35.2 K)
Net Cash Flow from Financing60.75 M42.92 M80 M143.9 M121.05 M130.6 M
Net Cash Flow from Investing15.21 M(2.1 M)(3.81 M)(12.72 M)(13.51 M)(13.87 M)
Net Cash Flow from Operations(37.27 M)(62.68 M)(76.19 M)(102 M)(112.37 M)(115.33 M)
Share Based Compensation1.56 M2.22 M2.65 M2.86 M3.49 M2.81 M

ADMA Biologics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ADMA Biologics's current stock value. Our valuation model uses many indicators to compare ADMA Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ADMA Biologics competition to find correlations between indicators driving ADMA Biologics's intrinsic value. More Info.
ADMA Biologics is rated second in number of shares shorted category among related companies. It is rated third in revenue category among related companies totaling about  3.72  of Revenue per Number of Shares Shorted. ADMA Biologics Revenues is projected to increase significantly based on the last few years of reporting. The past year's Revenues was at 80.94 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value ADMA Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ADMA Biologics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ADMA Biologics' earnings, one of the primary drivers of an investment's value.

ADMA Biologics Systematic Risk

ADMA Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ADMA Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on ADMA Biologics correlated with the market. If Beta is less than 0 ADMA Biologics generally moves in the opposite direction as compared to the market. If ADMA Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ADMA Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ADMA Biologics is generally in the same direction as the market. If Beta > 1 ADMA Biologics moves generally in the same direction as, but more than the movement of the benchmark.
.

About ADMA Biologics Financials

What exactly are ADMA Biologics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include ADMA Biologics' income statement, its balance sheet, and the statement of cash flows. Potential ADMA Biologics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although ADMA Biologics investors may use each financial statement separately, they are all related. The changes in ADMA Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ADMA Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as ADMA Biologics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of ADMA Biologics has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

ADMA Biologics December 5, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of ADMA Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ADMA Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of ADMA Biologics based on widely used predictive technical indicators. In general, we focus on analyzing ADMA Biologics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ADMA Biologics's daily price indicators and compare them against related drivers.
Downside Deviation3.61
Information Ratio0.0685
Maximum Drawdown30.82
Value At Risk(5.47)
Potential Upside7.2
Please continue to Trending Equities. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
661.2 M
Quarterly Revenue Growth YOY
0.99
Return On Assets
(0.11) 
Return On Equity
(0.69) 
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.